BIIB

#493
Biogen Inc. Common Stock
180.54 USD
+0.88%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
180.54
180.54
Rango anual
114.66
202.41
Cambio diario
+0.88%
Variación mensual
-1.21%
Variación en los últimos 6 meses
+25.33%
Cambio anual
+54.33%
Cierres anteriores
178.96
Abrir
180.54
Bid
Ask
Mínimo
180.54
High
180.54
Volumen
158
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM

Biogen Inc

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

Noticias